← All peptidesPDA-V1 attestation Citations
warningBioGate · AMBERGrade B
Abaloparatide (PTHrP analog, Tymlos)
AVSEHQLLHDKGKSIQDLRRRELLEKLLAKLHTAPTHrP analog with selective PTH1R RG conformation binding; faster anabolic effect with reduced hypercalcemia vs. teriparatide.
PTHrP-related synthetic 34-residue analog
MW
3961.00
Length
34aa
Posterior
40.8%
Structural preview · ESMFold-2 mockdeterministic per sequence
Backbone preview · PTHrP-related synthetic 34-residue analog
Cryptographic chain of custody.
- Outer PDA hash
- Inputs hash
- Merkle root
- TEE attestation
- Protocol version
- PDA-V1
- Source
- peptide-md
- Model version
- structure-fm-2026.04
- Candidates emitted
- 2
- Signed
- 2026-04-21T08:14:33Z
Verifiable in your browser at /verifier with
@peptide-md/verifier.Real-world evidence
Cohort-attested outcomes.
Cohorts
5
Participants
83
Mean Δ
+2.46
Δ HRV ms (8-week) · 95% CI [1.39, 3.53]
IPNFT · Molecule IPNFT V2Solana
Abaloparatide (PTHrP analog, Tymlos)
6e324e…806b32Royalty cascade
3.90%
Holders
267
Royalty cascade routes lab fees, licensing, and OEA-attested cohort revenues back to holders, the cohort treasury, and the originating researchers in a 60 / 25 / 15 split.
Source literature.
Grade A2016 · JAMA
Effect of Abaloparatide vs Placebo on New Vertebral Fractures (ACTIVE)
Miller PD et al.